Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vasiliki Spiliopoulou
Observed names:
V. Spiliopoulou,
Vassiliki Spiliopoulou
Institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital
Observed institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital,
University of Cincinnati,
University of Cincinnati Medical Center
ORCID:
0009-0009-5016-8729
Observed ORCID:
0009-0009-5016-8729
OpenAlex ID:
A5009776953
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation
2023
·
Evangelos Eleutherakis Papaiakovou
, Evangelos Terpos
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
30
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
2024
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Haematologica
·
19
PDF
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
2023
·
Ioannis Ntanasis-Stathopoulos
, Panagiotis Malandrakis
, et al.
·
International Journal of Molecular Sciences
·
18
PDF
Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring
2025
·
Efstathios Kastritis
, Irene Solia
, et al.
·
Blood Advances
·
17
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
2024
·
Ioannis V. Kostopoulos
, Ioannis Ntanasis‐Stathopoulos
, et al.
·
American Journal of Hematology
·
17
PDF
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
2023
·
Vassiliki Spiliopoulou
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Viruses
·
14
PDF
Outcomes of patients with light chain ( AL ) amyloidosis after failure of daratumumab‐based therapy
2023
·
Foteini Theodorakakou
, Despina Fotiou
, et al.
·
British Journal of Haematology
·
13
PDF
Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
2025
·
Meletios A. Dimopoulos
, Ioannis Ntanasis‐Stathopoulos
, et al.
·
American Journal of Hematology
·
12
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
2024
·
Efstathios Kastritis
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
9
PDF
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
2024
·
Maria Gavriatopoulou
, Ioannis Ntanasis‐Stathopoulos
, et al.
·
American Journal of Hematology
·
9
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
2023
·
Efstathios Kastritis
, Foteini Theodorakakou
, et al.
·
HemaSphere
·
9
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
2023
·
Efstathios Kastritis
, Maria Gavriatopoulou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
9
Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
2024
·
Panagiotis Malandrakis
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Blood
·
8
PDF
Prevalence of MGCS Among Patients With Monoclonal Gammopathies
2023
·
Foteini Theodorakakou
, Despina Fotiou
, et al.
·
HemaSphere
·
8
Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma
2025
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Blood
·
7
Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies
2025
·
Efstathios Kastritis
, Panagiotis Malandrakis
, et al.
·
Blood Cancer Journal
·
7
PDF
Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis
2025
·
Foteini Theodorakakou
, Despina Fotiou
, et al.
·
American Journal of Hematology
·
6
PDF
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
2023
·
Ioannis Ntanasis-Stathopoulos
, Charalampos Filippatos
, et al.
·
Diseases
·
6
PDF
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia
2025
·
Maria Gavriatopoulou
, Ioannis Ntanasis-Stathopoulos
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
5
PDF
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies
2025
·
Foteini Theodorakakou
, Despina Fotiou
, et al.
·
Amyloid
·
5
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high‐risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
2025
·
Efstathios Kastritis
, Charalampos Filippatos
, et al.
·
HemaSphere
·
4
Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice
2025
·
Ioannis Ntanasis-Stathopoulos
, Vassilis Koutoulidis
, et al.
·
Journal of Clinical Medicine
·
4
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis
2025
·
Despina Fotiou
, Foteini Theodorakakou
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
4
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.
2024
·
Evangelos Terpos
, Maria Gavriatopoulou
, et al.
·
Journal of Clinical Oncology
·
4
Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
2023
·
Efstathios Kastritis
, Panagiotis Malandrakis
, et al.
·
Blood
·
4
PDF
Show more works
View as search
Works count:
129
Citation count:
304
H-index:
9
I10-index:
8
Year
Topic
Type